Yang Mu-Zi, Hou Xue, Li Ji-Bin, Cai Jing-Sheng, Yang Jie, Li Shuo, Long Hao, Fu Jian-Hua, Zhang Lan-Jun, Lin Peng, Rong Tie-Hua, Yang Hao-Xian
Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
Eur J Cardiothorac Surg. 2020 Jun 1;57(6):1181-1188. doi: 10.1093/ejcts/ezaa008.
We investigated the impact of level 4 (L4) lymph node dissection (LND) on overall survival (OS) in left-side resectable non-small-cell lung cancer (NSCLC), with the aim of guiding lymphadenectomy.
A total of 1929 patients with left-side NSCLC who underwent R0 resection between 2001 and 2014 were included in the study. The patients were divided into a group with L4 LND (L4 LND+) and a group without L4 LND (L4 LND-). Propensity score matching was applied to minimize selection bias. The Kaplan-Meier method and Cox proportional hazards model were used to assess the impact of L4 LND on OS.
A total of 317 pairs were matched. Of the cohort of patients, 20.3% (391/1929) had L4 LND. Of these patients, 11.8% (46/391) presented with L4 lymph node metastasis. L4 lymph node metastasis was not associated with the primary tumour lobes (P = 0.61). Before propensity score matching, the 5-year OS was comparable between the L4 LND+ and L4 LND- groups (69.0% vs 65.2%, P = 0.091). However, after propensity score matching, the 5-year OS of the L4 LND+ group was much improved compared to that of the L4 LND- group (72.9% vs 62.3%, P = 0.002) and L4 LND was an independent factor favouring OS (hazard ratio 0.678, 95% confidence interval 0.513-0.897; P = 0.006). Subgroup analysis suggested that L4 LND was an independent factor favouring OS in left upper lobe tumours.
In patients with left-side operable NSCLC, L4 lymph node metastasis was not rare and L4 LND should be routinely performed.
我们研究了第4组(L4)淋巴结清扫术(LND)对左侧可切除非小细胞肺癌(NSCLC)总生存期(OS)的影响,旨在指导淋巴结切除术。
本研究纳入了2001年至2014年间接受R0切除的1929例左侧NSCLC患者。患者被分为接受L4 LND的组(L4 LND+)和未接受L4 LND的组(L4 LND-)。应用倾向评分匹配以尽量减少选择偏倚。采用Kaplan-Meier法和Cox比例风险模型评估L4 LND对OS的影响。
共匹配了317对。在患者队列中,20.3%(391/1929)接受了L4 LND。在这些患者中,11.8%(46/391)出现L4淋巴结转移。L4淋巴结转移与原发肿瘤叶无关(P = 0.61)。在倾向评分匹配前,L4 LND+组和L4 LND-组的5年总生存期相当(69.0%对65.2%,P = 0.091)。然而,在倾向评分匹配后,L4 LND+组的5年总生存期相比L4 LND-组有显著改善(72.9%对62.3%,P = 0.002),且L4 LND是有利于总生存期的独立因素(风险比0.678,95%置信区间0.513 - 0.897;P = 0.006)。亚组分析表明,L4 LND是左上叶肿瘤患者总生存期的独立有利因素。
在左侧可手术切除的NSCLC患者中,L4淋巴结转移并不罕见,应常规进行L4 LND。